China – the end of Animal Testing Requirements for Cosmetics?
Animal testing of cosmetics is already prohibited in the European Union for several years but, until now, it was mandatory to perform animal testing when making available a cosmetic product in the Chinese market. From 1st May (2021), animal testing will no longer be a requirement for ‘general’ cosmetics imported to China.

CHINA’S NEW ANIMAL TESTING POLICY

Animal testing was mandatory for all imported cosmetics before making them available in the Chinese market. China’s animal testing laws were aplicable to cosmetics sold in all physical retail stores, but not to cosmetics sold online or in Hong Kong, Macau and Taiwan. Chinese laws allowed companies to manufacture their products (general products previously known as ‘non-special use’) in China so they could avoid pre-market animal testing.

The implementation of a new Cosmetics Supervision and Administration Regulation (CSAR) has come into force on 1st of January (2021). On the 4th of March (2021) the National Medical Products Administration (NMPA) released the final versions of the two regulations: Provisions for Management of Cosmetic Registration and Notifications Dossiers (previously called as Instructions for Cosmetic Registration and Notification Dossiers) and Provisions for Management of New Cosmetic Ingredient Registration and Notifications Dossiers. The key goal of such regulations is to standardize and guide the registration and filing of new cosmetic materials and products. The documentation requirements for application, modification, renewal and cancellation of a cosmetic registration and notification are specified on these regulations. These sub-regulations under the CSAR are coming into force on May 1st (2021).

China’s new regulation states that animal testing will no longer be mandatory for imported ‘ordinary’ cosmetics. Data obtained from non-animal alternative methods will start to be accepted (conditionally) by authorities in order to register and notify new cosmetic ingredients.

The so called ‘ordinary’ or general’ cosmetics are defined as products that do not have specific claims (not used for a special purpose) such as skin whitening, anti-ageing and anti-acne, for example. Products like shampoo, body wash, lipstick, lotion and make up are considered ‘ordinary’ products; on the other hand, hair dyes, bleaching products, freckle-removal and whitening products, sunscreens and hair-loss products are ‘special products’ and still need to undergo animal testing in China.

Companies that want to qualify for animal testing exemption must fulfil two main requirements:

  • The safety assessment results have to fully confirm the safety of the product;
  • The manufacturer needs to have a certificate of Good Manufacturing Practice (GMP).

The required GMP certificate must be issued by the relevant regional or national authorities (and not by associations) from the country where the company is situated. This can be a problem, especially for companies located in European Union (EU) and United States (US), as usually the GMP certificates are not handed out by government agencies but by associations or private auditing companies. The French National Agency for the Safety of Medicines and Health Products (ANSM) will start to issue GMP certificates to manufacturers, which makes France the first country in the EU to be able to fulfil this requirement and qualify for exemptions on animal testing. This country has developed an online platform which will allow manufacturers to obtain GMP certificates.

Products that are intended to be used by children or infants are also excluded from the animal testing exemption. Moreover, animal testing needs to be performed in cosmetic products using new cosmetic ingredients (under a 3-year monitoring period) and whenever the notifier, responsible person or manufacturer is listed as a key supervision target according to NMPA’s quantitative rating system.

The NMPA stated that one of the main objectives of this new policy was to “fully consider and adopt the opinions of importing companies that some countries and regions have implemented the marketing ban on animal testing of cosmetics and cannot submit animal test data, and conditionally accept the toxicology test data of animal alternative methods”.

Although it does not cover all types of cosmetics, China’s new regulation is considered a major breakthrough and a step forward towards a worldwide “cruelty-free” and “animal-friendly” cosmetic industry.

References:

  1. China Finalizes Dossier Requirements for Registration and Notification of Cosmetics and New Cosmetic Ingredients. Chemlinked. Mar 04, 2021. Available at: https://cosmetic.chemlinked.com/news/cosmetic-news/china-finalizes-dossier-requirements-for-registration-and-notification-of-cosmetics-and-new-cosmetic-ingredients
  2. China animal testing: Exemptions for testing on ‘ordinary’ cosmetics star in May – officials. Cosmetics Design Asia. Mar 08, 2021. Available at: https://www.cosmeticsdesign-asia.com/Article/2021/03/08/China-animal-testing-Exemptions-for-testing-on-ordinary-cosmetics-start-in-May-officials
  3. China Announces New Animal Testing Policy for Cosmetics After PETA Push. People for the Ethical Treatment of Animas (PETA). Mar 08, 2021. Available at: https://www.peta.org/media/news-releases/china-announces-new-animal-testing-policy-for-cosmetics-after-peta-push/

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »